A clinical trial aiming to assess the effect of an immunotherapy for the treatment of soft tissue sarcomas treated by radiotherapy

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Centre Leon Berard

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

30 Jul 2018 → ongoing

Decision date (initial)

2024-10-28

Transition trial

Yes

Low-intervention

No

Rare-disease indication

Yes

Vulnerable population

No

Funding sources

F-Hoffman La ROCHE, Switzerland · Centre Léon Bérard (CLB)

External identifiers

EU CT number

2024-510713-15-00

EudraCT number

2016-005019-42

ClinicalTrials.gov

NCT03474094

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Safety, Efficacy, Pharmacodynamic, Therapy

To assess the clinical impact of PD-L1 neutralisation with or without radiotherapy versus radiotherapy alone based on the rate of pathological response defined by at least ≥80% pathologic necrosis on the surgery specimen

Secondary objectives 3

1. To evaluate the clinical activity of the proposed strategy
2. To assess the impact of study treatments on immune cell infiltration such as T cells (including but not limited to GmzB+ /CD8+ T-cell, CD3+ ), B cells (CD20, IgG), and Treg (FOXP3) on pre (de novo tumor biopsy at baseline) and post-treatment (surgery specimen) by immunofluorescence (IF)
3. To assess the safety and tolerability of proposed strategies in terms of Adverse Events (AE), Serious Adverse Events (SAEs). This will also include Incidence of acute wound complications up to 120 days after surgery

Conditions and MedDRA coding

Localised and operable soft tissue sarcomas

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 11

1. I1.Male or female patients aged ≥ 18 years at time of inform consent signature.
2. I2.Histologically confirmed soft tissue sarcoma including liposarcoma, leiomyosarcoma, myxofibrosarcoma, UPS, angiosarcoma, all translocation sarcoma except Ewing, rhabdomyosarcoma (RMS), and myxoid liposarcoma (LPS).
3. I3.Soft tissue sarcoma suitable for neoadjuvant RT and amenable to surgery with curative intent (high-grade non-metastatic tumors, intermediate and low-grade tumors greater than 5 cm. Note: Patients with local relapsing disease amenable to surgery are eligible.
4. I4.Presence of at least one tumor lesion with a diameter ≥10 mm, visible by medical imaging and accessible to percutaneous or endoscopic sampling that permit core needle biopsy without unacceptable risk and suitable for retrieval of a minimum of three, but ideally 4, cores using a biopsy needle of at least 16-gauge.
5. I5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
6. I6. Adequate end organs and bone marrow functions as defined below according to lab tests performed within 7 days before W1D1: ▪ Bone marrow (without transfusion within 2 weeks before W1D1): o Hemoglobin ≥ 9.0 g/dL, o Absolute neutrophil count ≥ 1.5 x 109 /L, o Platelets ≥ 100 x 109 /L, o Lymphocyte count ≥ 0.5 x 109 /L. ▪ Renal function: o Serum creatinine clearance ≥ 30 mL/min/1.73m2 (MDRD or CKD-EPI formula) ▪ Hepatic function o Serum bilirubin < 1.5 × Upper Limit of Normal (ULN), with the following exception: Patients with known Gilbert disease who have serum bilirubin level ≤ 3 ULN may be enrolled. o Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase ≤ 2.5 ULN. ▪ Coagulation o INR and aPTT ≤ 1.5 ULN Note: This is applicable only for patients not receiving an anticoagulant treatment: patients receiving therapeutic anticoagulation must be on stable dose.
7. I7. Minimal wash-out period for prior treatments (minimal time required from the end date of prior treatment to W1D1): ▪ Immunosuppressive medication > 28 days, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid, ▪ Live attenuated vaccines > 30 days, Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist® ) are live attenuated vaccines, and are not allowed. ▪ Major surgical procedure, open biopsy (excluding skin cancer resection and screening tumor biopsy), or significant traumatic injury > 14 days (the wound must have healed), ▪ Any approved or investigational anti-cancer therapy, including chemotherapy, hormonal therapy or targeted therapy > 21 days, ▪ Systemic immunostimulatory agents > 28 days or five halflives of the drug, whichever is longer, ▪ Oral or IV antibiotics > 14 days.
8. I8. Women of child-bearing potential must have a negative serum pregnancy test within 7 days before randomisation and must agree to use an effective form of contraception from the time of the negative pregnancy test up to 5 months after the last dose of atezolizumab.
9. I9. Fertile men must agree to use an effective method of birth control during the study and for up to 5 months after the last dose of atezolizumab.
10. I10. Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
11. I11. Patients must be covered by a medical insurance in country where applicable.

Exclusion criteria 16

1. E1. Patients with evidence of metastatic disease, defined by the presence of any of the followings: ▪ Lesions that are discontinuous from the primary tumor, ▪ Lesions that are not regional lymph nodes, ▪ Lesions that do not share a body cavity with the primary tumor, ▪ Evidence by medical imagining (eg CT-scan) of metastatic disease.
2. E2. Patients with history of severe allergic or other hypersensitivity reactions to: ▪ Chimeric or humanized antibodies or fusion proteins, ▪ Biopharmaceuticals produced in Chinese hamster ovary cells, or ▪ Any component of the atezolizumab formulation.
3. E3. Patients using or requirement to use while on the study of any not permitted concomitant medications : ▪ Any approved anti-cancer systemic treatment including chemotherapy, hormonotherapy, biological therapy, immunotherapy other than atezolizumab, ▪ Any investigational agents, ▪ Live vaccines. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines, and are not allowed during the study active period, ▪ Traditional herbal medicines since the ingredients of many herbal medicines are not fully studied and their use may result in unanticipated drug-drug interactions that may cause or confound assessment of toxicity, ▪ Immunostimulatory agents, including but not limited to IFNα, IFN-γ, or IL-2, during the entire study. These agents, in combination with atezolizumab, could potentially increase the risk for autoimmune conditions. In addition, all patients (including those who discontinue the study early) should not receive other immunostimulatory agents for 10 weeks after the last dose of atezolizumab, ▪ Immunosuppressive medications, including but not limited to cyclophosphamide, azathioprine, methotrexate, and thalidomide. These agents could potentially alter the activity and the safety of atezolizumab. Systemic corticosteroids and anti−TNF-α agents may attenuate potential beneficial immunologic effects of treatment with atezolizumab but may be administered to manage irAE (See Safety Plan). If feasible, alternatives to these agents should be considered.
4. E4. Patients with a malignancy other than STS within 5 years prior to randomisation with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated in situ carcinoma of the cervix, basal or squamous cell skin cancer, localised prostate cancer or ductal in situ carcinoma treated surgically with curative intent).
5. E5. Patients with severe infections within 4 weeks prior to randomisation including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia.
6. E6. Patients with history of autoimmune disease including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Note: Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: o Rash must cover less than 10% of body surface area (BSA). o Disease is well controlled at baseline and only requiring low potency topical steroids. o No acute exacerbations of underlying condition within the previous 12 months (not requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, high‑potency or oral steroids)” Note: Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible. Note: Patients with a type I diabetes well controlled by a stable dose of insulin are eligible.
7. E7. Patients with active B or C hepatitis infection. Note: Patients with past Hepatitis B Virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody test) are eligible. Patients positive for Hepatitis C Virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
8. E8. Patients with active tuberculosis.
9. E9. Patients with ongoing toxicities (Grade ≥1 according to CTCAE V5.0) from previous therapies, except for alopecia (any grades) and lab values defined in inclusion criteria. Note: Some Grade 2 may be permitted following discussion with the Sponsor.
10. E10. Patients with evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome).
11. E11. Patients with significant cardiovascular disease, such as New York Heart Association cardiac disease Class II or greater, myocardial infarction within 3 months prior to W1D1, unstable arrhythmias or unstable angina. Notes: ▪Patients with a known Left Ventricular Ejection Fraction (LVEF) < 40% will be excluded ▪Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF < 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate.
12. E12. Patients with history of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e. bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on imaging.
13. E13. Pregnant or lactating women.
14. E14. Prior organ transplantation including allogeneic stem cell transplantation.
15. E15. Patients who are known to be serologically positive for human immunodeficiency virus (HIV).
16. E16. Patient with prior treatment with anti−PD-1, or anti−PD-L1 immune checkpoint blockade therapies.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Rate of pathological response defined by at least ≥80% pathologic necrosis on the surgery specimen.

Secondary endpoints 3

1. - Rate of patients with complete or near-complete pathologic response defined as ≥ 95% tumor necrosis. - Rate of patients with at least ≥ 50% tumor necrosis . - Percentage of residual viable cells. - Objective Response Rate as RECIST v1.1. - Tumor volume change - Quality of resection and amputation rate. - Local Recurrence Rate (LRR) at 1 year post-surgery - Time To Relapse (TTR) - Disease Free Survival (DFS)
2. Evolution of number of T cells (including but not limited to GmzB+/CD8+ T-cell, CD3+), B cells (CD20, IgG), and Treg (FOXP3) on pre (de novo tumor biopsy at baseline) and post-treatment (surgery specimen) by immunofluorescence.
3. Incidene of Adverse Event (AE), Serious Adverse Events (SAEs), AESI and SUSARs.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Leon Berard

Sponsor organisation

Centre Leon Berard

Address

28 Rue Laennec

City

Lyon

Postcode

69008

Country

France

Scientific contact point

Organisation

Centre Leon Berard

Contact name

Pr Jean Yves BLAY

Public contact point

Organisation

Centre Leon Berard

Contact name

Clinical project manager

Locations

1 EU/EEA country · 6 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 6 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

1 submissions — initial application plus substantial / non-substantial modifications